The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.

Abstract

The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated. Non-Hodgkin lymphoma and Hodgkin lymphoma patients were divided into two groups as primary refractory and relapsed. The one-year overall survival was 100% (for relapsed) and 36.9% (for refractory) in the non-Hodgkin lymphoma groups, and 82.5% (for relapsed) and 80% (for refractory) in the Hodgkin lymphoma group. The one-year progression-free survival (PFS) was 72.7% (for relapsed) and 38.5% (for refractory) in patients with NHL, and 41% (for relapsed) and 18.2% (for refractory) in patients with HL. GDP/R-GDP seems to be a well-tolerated out-patient salvage regimen for relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma. Although proven efficacy, negative toxicity profile, and ease of administration, the application of gemcitabine-based therapy for patients with primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma provided limited success.

• Authors: Hikmettullah Batgi, Alparslan Merdin, Mehmet Sinan Dal, Merih Kızıl Çakar, Jale Yıldız, Semih Başçı, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Tahir Darçın, Derya Şahin, Mehmet Bakırtaş, Ayşegül Tetik, Dicle İskender, Fevzi Altuntaş
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 26 Issue 8 Pg. 1857-1863 (Dec 2020) ISSN: 1477-092X [Electronic] England
• PMID: 32098553 (Publication Type: Journal Article)

Chemical References

• Deoxycytidine
• Dexamethasone
• Cisplatin
• Gemcitabine

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Cisplatin (administration & dosage)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Dexamethasone (administration & dosage)
• Female
• Hodgkin Disease (drug therapy)
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Retrospective Studies
• Salvage Therapy (adverse effects, methods)
• Young Adult
• Gemcitabine